About Revolution Medicines Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.revmed.com/
Frequently Asked Questions
What is the 52-week range for RVMD?
The 52-week high is $224.31 and the 52-week low is $45.605.
What is the P/E ratio for RVMD?
The P/E ratio data is currently unavailable.
What is the dividend yield for RVMD?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -54.06%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -2833.88%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 9.44.
Analyst Recommendation Trends
Wall Street analyst consensus for RVMD over the last few months:
Latest RVMD News
Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says
Revolution Medicines (RVMD) is expected to have a "strong" launch for its Rasonque drug in second-li
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318
Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?
Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation. IDEAYA Biosciences (NASDAQ:IDYA) operates from a position of relative balance sheet strength, backed by $1.24 billion in cash, cash equivalents, and marketable securities that extend its […]
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.
Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?
Revolution Medicines (RVMD) just picked up Breakthrough Therapy Designation from the FDA for RASONQUE in treatment naïve metastatic pancreatic adenocarcinoma, a cancer setting with limited options and intense clinical interest. That regulatory progress is landing against a mixed tape for Revolution Medicines, with the share price easing 5.9% over the past week and 7.9% over the past month, yet still showing strong momentum overall through a 13.6% 3 month share price return and a very large 1...
Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?
Earlier in September 2026, Revolution Medicines announced that the FDA granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib) plus chemotherapy for treatment‑naïve metastatic pancreatic adenocarcinoma, adding to its existing U.S. approval in later‑line PDAC. The company was also added to the FTSE All‑World Index (USD), potentially broadening its shareholder base as it advances a late‑stage RAS(ON) pipeline in a cancer with very limited treatment options. With Breakthrough...
Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE
Revolution Medicines (NasdaqGS: RVMD) received FDA Breakthrough Therapy Designation for RASONQUE (daraxonrasib) in metastatic pancreatic adenocarcinoma. The designation covers RASONQUE in combination with existing chemotherapy for patients who have not previously received treatment. Breakthrough Therapy status may provide access to expedited FDA interactions and review processes for this treatment candidate. The Breakthrough Therapy Designation for RASONQUE in first line metastatic...
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in a selected pancreatic patient population versus 12.5 months in historical controls OCALA, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a letter to stockholders from Chief Executive Officer Thomas Equels a
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Dataset MELBOURNE, Australia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of l
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 33.5% on an annualized basis producing an average annual return of 45.32%. Currently, Revolution Medicines has a market
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265
B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $225 to $265.
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
This company has succeeded where many others have failed.
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to RAS(ON) & Pan-RAS TherapiesMELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a co
Baron Health Care Fund Q2 2026 Portfolio Activity
During the quarter, we added 8 new positions and exited 6 positions, bringing the number of positions in the Fund to 43.
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for patients with RAS-addicted cancers REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cance
MarketBeat Week in Review – 09/07 - 09/11
Stocks fell this week on oil prices and Fed rate-hike expectations, though Oracle's earnings underscored AI infrastructure strength. MarketBeat analysts recap top stories on earnings, defense, AI, and other stock opportunities.
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs
Reuters reported that the FDA approved Revolution Medicines, Inc. (NASDAQ:RVMD) Rasonque (daraxonrasib) on August 26 for adults with metastatic pancreatic cancer who have already received prior treatment or cannot receive combination chemotherapy. The once-daily pill is the first broad RAS-targeted medicine approved for pancreatic cancer, designed to block several forms of the RAS protein that […]
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.
IHE: Innovation Supports The Outlook, Valuation Limits Conviction
IHE trades at a P/E of 16.11x and is rated HOLD due to regulatory, patent, and concentration risks. Click for more details on the IHE fund.
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More.
Fresh off a regulatory victory for its groundbreaking cancer drug, Revolution Medicines could capture even more of the oncology market.
Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says
Revolution Medicines (RVMD) could see strong long-term growth from Rasonque sales, expansion into ea
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255
Morgan Stanley analyst Sean Laaman initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $255.
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230
Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $215 to $230.
Revolution Medicines (RVMD) Stock Looks Overvalued Even After Its Drug Approval
Revolution Medicines has delivered very large share price gains over the past few years, while broad valuation checks currently suggest the stock leans expensive rather than offering clear value. For investors, the question is how to balance that strong share price history against what the recent valuation signals are implying today. Over the past 5 years, Revolution Medicines has returned about 6x, which sets a high bar for any further upside from here. The recent FDA approval for Rasonque...
Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal
Revolution Medicines (NasdaqGS:RVMD) reported US FDA approval of RASONQUE for adults with previously treated metastatic pancreatic adenocarcinoma, the first broad RAS targeted therapy for this cancer type. RASONQUE is the first approved therapy from a new class of RAS(ON) multi selective inhibitors aimed at tumors driven by RAS mutations. Phase 1/2 clinical data for RASONQUE in RAS mutant non small cell lung cancer were published in the New England Journal of Medicine, providing independent...
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?
Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review. The once-daily oral RAS inhibitor is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Revolution Medicines, Inc. (NASDAQ:RVMD) set a wholesale acquisition cost (WAC) […]
Revolution Medicines Got Its Breakthrough—What Moves It Next?
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.53% on an annualized basis producing an average annual return of 46.85%. Currently, Revolution Medicines has a market
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer
Sen. Bernie Sanders (I-VT) expressed his concern over the financial burden of cancer treatment in the U.S., attributing it to the high cost of new drugs. Sanders took to X to talk about the financial strain cancer patients face due...
Reported Earlier, Revolution Medicines Lung Cancer Drug Shows 42% Response Rate In Early Trial
Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-29 | Sandler Alan B. | -6,000 | - | - |
| 2026-09-29 | Sandler Alan B. | -301 | $204.7224 | $61,621 |
| 2026-09-29 | Sandler Alan B. | -1,199 | $203.9074 | $244,485 |
| 2026-09-29 | Sandler Alan B. | -1,000 | $202.8127 | $202,813 |
| 2026-09-29 | Sandler Alan B. | -1,609 | $201.7239 | $324,574 |
| 2026-09-29 | Sandler Alan B. | -2,200 | $200.8188 | $441,801 |
| 2026-09-29 | Sandler Alan B. | +6,000 | $58.84 | $353,040 |
| 2026-09-25 | Cislini Jeff | -765 | $207.3201 | $158,600 |
| 2026-09-25 | Mancini Anthony | -3,121 | - | - |
| 2026-09-25 | Mancini Anthony | -3,121 | $200.54 | $625,885 |
| 2026-09-25 | Mancini Anthony | +3,121 | $33.62 | $104,928 |
| 2026-09-24 | Mancini Anthony | -587 | $200 | $117,400 |
| 2026-09-22 | ANDERSON ELIZABETH M | -5,070 | - | - |
| 2026-09-22 | ANDERSON ELIZABETH M | -100 | $195.15 | $19,515 |
| 2026-09-22 | ANDERSON ELIZABETH M | -1,500 | $194.5887 | $291,883 |
| 2026-09-22 | ANDERSON ELIZABETH M | -2,648 | $193.4392 | $512,227 |
| 2026-09-22 | ANDERSON ELIZABETH M | -4,985 | $192.5387 | $959,805 |
| 2026-09-22 | ANDERSON ELIZABETH M | -910 | $191.8521 | $174,585 |
| 2026-09-22 | ANDERSON ELIZABETH M | +5,070 | $1.12 | $5,678 |
| 2026-09-18 | Mancini Anthony | -1,764 | $196.94 | $347,402 |
| 2026-09-16 | Mancini Anthony | -1,747 | $199.3032 | $348,183 |
| 2026-09-16 | Mancini Anthony | -27 | $195.0521 | $5,266 |
| 2026-09-16 | Cislini Jeff | -3,314 | $199.3032 | $660,491 |
| 2026-09-16 | Cislini Jeff | -52 | $195.0087 | $10,140 |
| 2026-09-16 | Sandler Alan B. | -336 | $199.3032 | $66,966 |
| 2026-09-16 | Sandler Alan B. | -5 | $194.9589 | $975 |
| 2026-09-16 | Anders Jack | -3,992 | $199.3032 | $795,618 |
| 2026-09-16 | Anders Jack | -61 | $195 | $11,895 |
| 2026-09-16 | Kelsey Stephen Michael | -5,484 | $199.3032 | $1,092,979 |
| 2026-09-16 | Kelsey Stephen Michael | -85 | $195.0074 | $16,576 |
| 2026-09-16 | Horn Margaret A | -4,891 | $199.3032 | $974,792 |
| 2026-09-16 | Horn Margaret A | -76 | $195.0083 | $14,821 |
| 2026-09-16 | GOLDSMITH MARK A | -13,775 | $199.3032 | $2,745,402 |
| 2026-09-16 | GOLDSMITH MARK A | -213 | $195.0085 | $41,537 |
| 2026-09-11 | Kelsey Stephen Michael | -40,031 | $40.74 | $1,630,863 |
| 2026-09-11 | Kelsey Stephen Michael | -52,500 | $42.45 | $2,228,625 |
| 2026-09-11 | Kelsey Stephen Michael | -3,270 | $205.8075 | $672,991 |
| 2026-09-11 | Kelsey Stephen Michael | -4,995 | $204.8427 | $1,023,189 |
| 2026-09-11 | Kelsey Stephen Michael | -17,949 | $203.8726 | $3,659,309 |
| 2026-09-11 | Kelsey Stephen Michael | -18,869 | $203.0606 | $3,831,550 |
| 2026-09-11 | Kelsey Stephen Michael | -21,447 | $201.7507 | $4,326,947 |
| 2026-09-11 | Kelsey Stephen Michael | -13,368 | $200.7769 | $2,683,986 |
| 2026-09-11 | Kelsey Stephen Michael | -11,833 | $200.1145 | $2,367,955 |
| 2026-09-11 | Kelsey Stephen Michael | -800 | $198.5502 | $158,840 |
| 2026-09-11 | Kelsey Stephen Michael | +40,031 | $40.74 | $1,630,863 |
| 2026-09-11 | Kelsey Stephen Michael | +52,500 | $42.45 | $2,228,625 |
| 2026-09-10 | Mancini Anthony | -9,363 | - | - |
| 2026-09-10 | Mancini Anthony | -300 | $207.1733 | $62,152 |
| 2026-09-10 | Mancini Anthony | -1,179 | $206.0995 | $242,991 |
| 2026-09-10 | Mancini Anthony | -2,420 | $205.0513 | $496,224 |
| 2026-09-10 | Mancini Anthony | -5,530 | $204.1357 | $1,128,870 |
| 2026-09-10 | Mancini Anthony | -6,019 | $203.2844 | $1,223,569 |
| 2026-09-10 | Mancini Anthony | +9,363 | $33.62 | $314,784 |
| 2026-09-08 | Kim Lorence H. | -371 | $212.2693 | $78,752 |
| 2026-09-08 | Kim Lorence H. | -3,844 | $211.3588 | $812,463 |
| 2026-09-08 | Kim Lorence H. | -4,730 | $210.5028 | $995,678 |
| 2026-09-08 | Kim Lorence H. | -2,853 | $209.56 | $597,875 |
| 2026-09-08 | Kim Lorence H. | -3,587 | $208.5534 | $748,081 |
| 2026-09-08 | Kim Lorence H. | -999 | $207.3321 | $207,125 |
| 2026-09-08 | Kim Lorence H. | -706 | $206.6049 | $145,863 |
| 2026-08-31 | Kim Lorence H. | -625 | $206.154 | $128,846 |
| 2026-08-31 | Kim Lorence H. | -2,128 | $205.1879 | $436,640 |
| 2026-08-31 | Kim Lorence H. | -7,271 | $204.3501 | $1,485,830 |
| 2026-08-31 | Kim Lorence H. | -26,160 | $203.5483 | $5,324,824 |
| 2026-08-31 | Kim Lorence H. | -12,919 | $202.4819 | $2,615,864 |
| 2026-08-31 | Kim Lorence H. | -6,597 | $201.4729 | $1,329,117 |
| 2026-08-31 | Kim Lorence H. | -300 | $200.56 | $60,168 |
| 2026-08-21 | Cislini Jeff | -26,600 | - | - |
| 2026-08-21 | Cislini Jeff | -29,680 | - | - |
| 2026-08-21 | Cislini Jeff | -3,314 | $212.0583 | $702,761 |
| 2026-08-21 | Cislini Jeff | -4,500 | $211.3417 | $951,038 |
| 2026-08-21 | Cislini Jeff | -2,540 | $210.2647 | $534,072 |
| 2026-08-21 | Cislini Jeff | -25,817 | $209.2497 | $5,402,200 |
| 2026-08-21 | Cislini Jeff | -17,323 | $208.3688 | $3,609,573 |
| 2026-08-21 | Cislini Jeff | -3,400 | $207.2363 | $704,603 |
| 2026-08-21 | Cislini Jeff | +26,600 | $21.61 | $574,826 |
| 2026-08-21 | Cislini Jeff | +29,680 | $18.56 | $550,861 |
| 2026-08-21 | GOLDSMITH MARK A | -80,000 | - | - |
| 2026-08-21 | GOLDSMITH MARK A | -126 | $212.0641 | $26,720 |
| 2026-08-21 | GOLDSMITH MARK A | -229 | $211.4648 | $48,425 |
| 2026-08-21 | GOLDSMITH MARK A | -126 | $210.403 | $26,511 |
| 2026-08-21 | GOLDSMITH MARK A | -1,405 | $209.2664 | $294,019 |
| 2026-08-21 | GOLDSMITH MARK A | -937 | $208.3609 | $195,234 |
| 2026-08-21 | GOLDSMITH MARK A | -177 | $207.2515 | $36,684 |
| 2026-08-21 | GOLDSMITH MARK A | -127 | $212.0635 | $26,932 |
| 2026-08-21 | GOLDSMITH MARK A | -245 | $211.4651 | $51,809 |
| 2026-08-21 | GOLDSMITH MARK A | -136 | $210.4017 | $28,615 |
| 2026-08-21 | GOLDSMITH MARK A | -1,351 | $209.2812 | $282,739 |
| 2026-08-21 | GOLDSMITH MARK A | -951 | $208.3648 | $198,155 |
| 2026-08-21 | GOLDSMITH MARK A | -190 | $207.2454 | $39,377 |
| 2026-08-21 | GOLDSMITH MARK A | -3,621 | $212.0776 | $767,933 |
| 2026-08-21 | GOLDSMITH MARK A | -6,583 | $211.3331 | $1,391,206 |
| 2026-08-21 | GOLDSMITH MARK A | -3,813 | $210.2466 | $801,670 |
| 2026-08-21 | GOLDSMITH MARK A | -35,938 | $209.2615 | $7,520,440 |
| 2026-08-21 | GOLDSMITH MARK A | -24,917 | $208.3697 | $5,191,948 |
| 2026-08-21 | GOLDSMITH MARK A | -5,128 | $207.233 | $1,062,691 |
| 2026-08-21 | GOLDSMITH MARK A | +80,000 | $4.73 | $378,400 |
| 2026-06-29 | Patel Sushil | -2,955 | - | - |
| 2026-06-29 | Patel Sushil | -881 | $192.6139 | $169,693 |
| 2026-06-29 | Patel Sushil | -541 | $191.8661 | $103,800 |
| 2026-06-29 | Patel Sushil | -600 | $190.545 | $114,327 |
| 2026-06-29 | Patel Sushil | -100 | $188.57 | $18,857 |
| 2026-06-29 | Patel Sushil | -300 | $187.8267 | $56,348 |
| 2026-06-29 | Patel Sushil | -858 | $186.9157 | $160,374 |
| 2026-06-29 | Patel Sushil | -1,100 | $185.8991 | $204,489 |
| 2026-06-29 | Patel Sushil | -900 | $184.5869 | $166,128 |
| 2026-06-29 | Patel Sushil | -300 | $183.1733 | $54,952 |
| 2026-06-29 | Patel Sushil | +2,955 | $37.54 | $110,931 |
| 2026-06-24 | Anders Jack | +20,000 | - | - |
| 2026-06-24 | Anders Jack | -300 | $170.32 | $51,096 |
| 2026-06-24 | Anders Jack | -5,651 | $169.2441 | $956,398 |
| 2026-06-24 | Anders Jack | -9,496 | $168.1959 | $1,597,188 |
| 2026-06-24 | Anders Jack | -4,553 | $167.345 | $761,922 |
| 2026-06-24 | Anders Jack | +20,000 | $18.56 | $371,200 |
| 2026-06-18 | Kim Lorence H. | +3,127 | - | - |
| 2026-06-18 | Kim Lorence H. | +1,191 | - | - |
| 2026-06-18 | ANDERSON ELIZABETH M | +3,127 | - | - |
| 2026-06-18 | ANDERSON ELIZABETH M | +1,191 | - | - |
| 2026-06-18 | Horning Sandra | +3,127 | - | - |
| 2026-06-18 | Horning Sandra | +1,191 | - | - |
| 2026-06-18 | Clyburn Frank | +3,127 | - | - |
| 2026-06-18 | Clyburn Frank | +1,191 | - | - |
| 2026-06-18 | Patel Sushil | +3,127 | - | - |
| 2026-06-18 | Patel Sushil | +1,191 | - | - |
| 2026-06-18 | Borellini Flavia | +3,127 | - | - |
| 2026-06-18 | Borellini Flavia | +1,191 | - | - |
| 2026-06-18 | Borisy Alexis | +3,127 | - | - |
| 2026-06-18 | Borisy Alexis | +1,191 | - | - |
| 2026-06-17 | Horn Margaret A | -25,725 | - | - |
| 2026-06-17 | Horn Margaret A | -3,302 | - | - |
| 2026-06-17 | Horn Margaret A | -573 | - | - |
| 2026-06-17 | Horn Margaret A | -29,600 | $160.1243 | $4,739,679 |
| 2026-06-17 | Horn Margaret A | +25,725 | $26.5 | $681,713 |
| 2026-06-17 | Horn Margaret A | +3,302 | $29.8 | $98,400 |
| 2026-06-17 | Horn Margaret A | +573 | $40.74 | $23,344 |
| 2026-06-16 | Mancini Anthony | -4,615 | $156.1192 | $720,490 |
| 2026-06-16 | Cislini Jeff | -2,157 | $156.1191 | $336,749 |
| 2026-06-16 | Anders Jack | -2,722 | $156.1192 | $424,956 |
| 2026-06-16 | Kelsey Stephen Michael | -4,175 | $156.1192 | $651,798 |
| 2026-06-16 | GOLDSMITH MARK A | -10,020 | $156.1188 | $1,564,310 |
| 2026-06-15 | Horn Margaret A | -44,854 | - | - |
| 2026-06-15 | Horn Margaret A | -15,546 | - | - |
| 2026-06-15 | Horn Margaret A | -60,400 | $160.1706 | $9,674,304 |
| 2026-06-15 | Horn Margaret A | +44,854 | $29.8 | $1,336,649 |
| 2026-06-15 | Horn Margaret A | +15,546 | $40.74 | $633,344 |
| 2026-06-11 | Horn Margaret A | -8,906 | - | - |
| 2026-06-11 | Horn Margaret A | -1,094 | - | - |
| 2026-06-11 | Horn Margaret A | -200 | $150.17 | $30,034 |
| 2026-06-11 | Horn Margaret A | -4,600 | $149.6429 | $688,357 |
| 2026-06-11 | Horn Margaret A | -1,800 | $148.7231 | $267,702 |
| 2026-06-11 | Horn Margaret A | -500 | $147.272 | $73,636 |
| 2026-06-11 | Horn Margaret A | -700 | $146.0371 | $102,226 |
| 2026-06-11 | Horn Margaret A | -885 | $145.1495 | $128,457 |
| 2026-06-11 | Horn Margaret A | -1,315 | $144.2793 | $189,727 |
| 2026-06-11 | Horn Margaret A | +8,906 | $40.74 | $362,830 |
| 2026-06-11 | Horn Margaret A | +1,094 | $42.45 | $46,440 |
| 2026-05-26 | Mancini Anthony | -3,121 | - | - |
| 2026-05-26 | Mancini Anthony | -421 | $154.8157 | $65,177 |
| 2026-05-26 | Mancini Anthony | -2,000 | $154.0609 | $308,122 |
| 2026-05-26 | Mancini Anthony | -700 | $153.3023 | $107,312 |
| 2026-05-26 | Mancini Anthony | +3,121 | $33.62 | $104,928 |
| 2026-04-27 | Mancini Anthony | -3,120 | - | - |
| 2026-04-27 | Mancini Anthony | -400 | $134.335 | $53,734 |
| 2026-04-27 | Mancini Anthony | -1,049 | $132.8768 | $139,388 |
| 2026-04-27 | Mancini Anthony | -1,671 | $131.6619 | $220,007 |
| 2026-04-27 | Mancini Anthony | +3,120 | $33.62 | $104,894 |
| 2026-04-15 | GOLDSMITH MARK A | -96,756 | - | - |
| 2026-04-15 | GOLDSMITH MARK A | -23,244 | - | - |
| 2026-04-15 | GOLDSMITH MARK A | -120,000 | $150.0874 | $18,010,488 |
| 2026-04-15 | GOLDSMITH MARK A | +96,756 | $4.73 | $457,656 |
| 2026-04-15 | GOLDSMITH MARK A | +23,244 | $4.09 | $95,068 |
| 2026-03-25 | Mancini Anthony | -37,450 | - | - |
| 2026-03-25 | Mancini Anthony | -400 | $97.2071 | $38,883 |
| 2026-03-25 | Mancini Anthony | -11,036 | $96.4299 | $1,064,200 |
| 2026-03-25 | Mancini Anthony | -21,086 | $95.4859 | $2,013,416 |
| 2026-03-25 | Mancini Anthony | -3,128 | $94.1561 | $294,520 |
| 2026-03-25 | Mancini Anthony | -1,800 | $93.223 | $167,801 |
| 2026-03-25 | Mancini Anthony | +37,450 | $33.62 | $1,259,069 |
| 2026-03-19 | Cislini Jeff | -1,163 | $97.44 | $113,323 |
| 2026-03-17 | Wei Lin | -2,073 | $99.4804 | $206,223 |
| 2026-03-17 | Anders Jack | -2,753 | $99.4804 | $273,870 |
| 2026-03-17 | Cislini Jeff | -1,795 | $99.4804 | $178,567 |
| 2026-03-17 | Wang Xiaolin | -2,010 | $99.4804 | $199,956 |
| 2026-03-17 | Kelsey Stephen Michael | -4,302 | $99.4804 | $427,965 |
| 2026-03-17 | Horn Margaret A | -4,583 | $99.4804 | $455,919 |
| 2026-03-17 | GOLDSMITH MARK A | -12,871 | $99.4804 | $1,280,412 |
| 2026-03-04 | ANDERSON ELIZABETH M | +15,000 | - | - |
| 2026-03-04 | ANDERSON ELIZABETH M | -15,000 | - | - |
| 2026-03-02 | GOLDSMITH MARK A | -30,000 | - | - |
| 2026-03-02 | GOLDSMITH MARK A | -200 | $102.08 | $20,416 |
| 2026-03-02 | GOLDSMITH MARK A | -2,100 | $101.6341 | $213,432 |
| 2026-03-02 | GOLDSMITH MARK A | -600 | $100.1933 | $60,116 |
| 2026-03-02 | GOLDSMITH MARK A | -100 | $98.29 | $9,829 |
| 2026-03-02 | GOLDSMITH MARK A | -800 | $101.9983 | $81,599 |
| 2026-03-02 | GOLDSMITH MARK A | -1,700 | $101.4743 | $172,506 |
| 2026-03-02 | GOLDSMITH MARK A | -400 | $100.1225 | $40,049 |
| 2026-03-02 | GOLDSMITH MARK A | -100 | $98.31 | $9,831 |
| 2026-03-02 | GOLDSMITH MARK A | -851 | $102.1994 | $86,972 |
| 2026-03-02 | GOLDSMITH MARK A | -21,329 | $101.6023 | $2,167,075 |
| 2026-03-02 | GOLDSMITH MARK A | -3,620 | $100.7346 | $364,659 |
| 2026-03-02 | GOLDSMITH MARK A | -3,500 | $99.7572 | $349,150 |
| 2026-03-02 | GOLDSMITH MARK A | -700 | $98.1708 | $68,720 |
| 2026-03-02 | GOLDSMITH MARK A | +30,000 | $4.09 | $122,700 |
| 2026-03-01 | Wang Xiaolin | +34,000 | - | - |
| 2026-03-01 | Wang Xiaolin | +15,100 | - | - |
| 2026-03-01 | Wei Lin | +34,000 | - | - |
| 2026-03-01 | Wei Lin | +15,100 | - | - |
| 2026-03-01 | Cislini Jeff | +32,500 | - | - |
| 2026-03-01 | Cislini Jeff | +14,500 | - | - |
| 2026-03-01 | Anders Jack | +45,400 | - | - |
| 2026-03-01 | Anders Jack | +20,200 | - | - |
| 2026-03-01 | Kelsey Stephen Michael | +47,600 | - | - |
| 2026-03-01 | Kelsey Stephen Michael | +21,100 | - | - |
| 2026-03-01 | Horn Margaret A | +47,600 | - | - |
| 2026-03-01 | Horn Margaret A | +21,100 | - | - |
| 2026-03-01 | GOLDSMITH MARK A | +128,600 | - | - |
| 2026-03-01 | GOLDSMITH MARK A | +57,100 | - | - |
| 2026-02-06 | GOLDSMITH MARK A | -24,010 | - | - |
| 2026-02-06 | GOLDSMITH MARK A | +24,010 | $0.54 | $12,965 |
| 2026-01-21 | Cislini Jeff | -908 | $115.6 | $104,965 |
| 2026-01-07 | Anders Jack | -10,000 | - | - |
| 2026-01-07 | Anders Jack | -10,000 | $98 | $980,000 |
| 2026-01-07 | Anders Jack | +10,000 | $42.45 | $424,500 |
| 2026-01-07 | Horn Margaret A | -23,594 | - | - |
| 2026-01-07 | Horn Margaret A | -51,406 | - | - |
| 2026-01-07 | Horn Margaret A | -1,700 | $102.9 | $174,930 |
| 2026-01-07 | Horn Margaret A | -20,204 | $101.7928 | $2,056,622 |
| 2026-01-07 | Horn Margaret A | -53,096 | $100.0164 | $5,310,471 |
| 2026-01-07 | Horn Margaret A | +23,594 | $29.8 | $703,101 |
| 2026-01-07 | Horn Margaret A | +51,406 | $42.45 | $2,182,185 |
| 2025-12-16 | Cislini Jeff | -2,688 | $76.8169 | $206,484 |
| 2025-12-16 | Anders Jack | -3,104 | $77.0904 | $239,289 |
| 2025-12-16 | Kelsey Stephen Michael | -5,447 | $76.8172 | $418,423 |
| 2025-12-16 | Horn Margaret A | -4,847 | $76.8173 | $372,333 |
| 2025-12-16 | GOLDSMITH MARK A | -15,394 | $76.8173 | $1,182,526 |
| 2025-11-25 | Anders Jack | -5,418 | - | - |
| 2025-11-25 | Anders Jack | -5,418 | $74 | $400,932 |
| 2025-11-25 | Anders Jack | +5,418 | $17 | $92,106 |
| 2025-11-25 | GOLDSMITH MARK A | -60,000 | - | - |
| 2025-11-25 | GOLDSMITH MARK A | -3,000 | $75 | $225,000 |
| 2025-11-25 | GOLDSMITH MARK A | -3,000 | $75 | $225,000 |
| 2025-11-25 | GOLDSMITH MARK A | -60,000 | $75.0827 | $4,504,962 |
| 2025-11-25 | GOLDSMITH MARK A | +60,000 | $4.09 | $245,400 |
| 2025-11-18 | Cislini Jeff | -13,388 | - | - |
| 2025-11-18 | Cislini Jeff | -13,388 | $70.138 | $939,008 |
| 2025-11-18 | Cislini Jeff | +13,388 | $42.45 | $568,321 |
| 2025-11-18 | GOLDSMITH MARK A | -20,000 | - | - |
| 2025-11-18 | GOLDSMITH MARK A | -20,000 | $70.3793 | $1,407,586 |
| 2025-11-18 | GOLDSMITH MARK A | +20,000 | $4.09 | $81,800 |
| 2025-11-12 | GOLDSMITH MARK A | -20,000 | - | - |
| 2025-11-12 | GOLDSMITH MARK A | -20,000 | $65.0705 | $1,301,410 |
| 2025-11-12 | GOLDSMITH MARK A | +20,000 | $4.09 | $81,800 |
| 2025-11-12 | GOLDSMITH MARK A | +50,000 | - | - |
| 2025-11-12 | GOLDSMITH MARK A | +50,000 | - | - |
| 2025-11-12 | GOLDSMITH MARK A | -50,000 | - | - |
| 2025-11-12 | GOLDSMITH MARK A | -50,000 | - | - |
| 2025-11-11 | Anders Jack | -10,000 | - | - |
| 2025-11-11 | Anders Jack | -10,000 | $64 | $640,000 |
| 2025-11-11 | Anders Jack | +10,000 | $17 | $170,000 |
| 2025-11-07 | GOLDSMITH MARK A | -3,521 | - | - |
| 2025-11-07 | GOLDSMITH MARK A | -26,479 | - | - |
| 2025-11-07 | GOLDSMITH MARK A | -30,000 | $60.3102 | $1,809,306 |
| 2025-11-07 | GOLDSMITH MARK A | +3,521 | $4.09 | $14,401 |
| 2025-11-07 | GOLDSMITH MARK A | +26,479 | $1.12 | $29,656 |
| 2025-10-17 | Cislini Jeff | -12,000 | - | - |
| 2025-10-17 | Cislini Jeff | -12,000 | $55 | $660,000 |
| 2025-10-17 | Cislini Jeff | +12,000 | $36.57 | $438,840 |
| 2025-10-17 | GOLDSMITH MARK A | -10,000 | - | - |
| 2025-10-17 | GOLDSMITH MARK A | -10,000 | $55 | $550,000 |
| 2025-10-17 | GOLDSMITH MARK A | +10,000 | $1.12 | $11,200 |
| 2025-10-16 | GOLDSMITH MARK A | -10,000 | - | - |
| 2025-10-16 | GOLDSMITH MARK A | -10,000 | $50.4701 | $504,701 |
| 2025-10-16 | GOLDSMITH MARK A | +10,000 | $1.12 | $11,200 |
| 2025-10-13 | Kelsey Stephen Michael | -25,000 | - | - |
| 2025-10-13 | Kelsey Stephen Michael | -25,000 | $48.5416 | $1,213,540 |
| 2025-10-13 | Kelsey Stephen Michael | +25,000 | $4.73 | $118,250 |